GLOW legal status: the GLOW peptide FDA record
An ingredient can leave a table without becoming approved. The precise status matters more than the reassuring version of the story.
What a patient-by-patient pharmacy may do now
A pharmacy may make a drug for one patient when a standard product does not fit that care. For GLOW, Promise Peptides (mypromise.com) now prescribes the GHK-Cu, BPC-157 and TB-500 injection blend after a licensed U.S. clinician assesses the individual request. A refusal is possible; this care accepts U.S. patients, with choices shaped by the state and treatment.
The FDA's published advisory agenda names BPC-157 and TB-500 as candidates for the 503A bulk list [13]. An advisory agenda is not a final FDA listing decision. The agency calls it the 503A bulk list for pharmacies that fill one patient’s prescription.
The FDA's current safety page places all three shot ingredients in its nominated-but-withdrawn table [11][12]. Its safety concerns remain online for patients and pharmacies to read. Withdrawal did not approve the ingredients or add them to the allowed list.
A prescribing service must meet the rules for each ingredient and each patient's care. A discussion by FDA advisers grants no new compounding permission. A pharmacy remains responsible for meeting the federal and state rules that apply.
The table changed; approval did not appear
On FDA's page current as of April 22, 2026, BPC-157, TB-500 and GHK-Cu for injectable routes are in the nominated-but-withdrawn table, outside the current Category 2 table. FDA still publishes its safety concerns. There is no published date establishing when each entry moved out of Category 2.
Withdrawal carries less reassurance than its retelling suggests. Withdrawal does not grant Category 1 standing, add an ingredient to the 503A bulk list or approve it as a drug. These withdrawn nominations are no longer being evaluated for that list. The 503A framework and the safety record need to be read together.
Category 1 concerns nominated substances under an interim policy while FDA evaluation continues. Category 2 concerns substances raising significant safety risks and does not carry that interim pause on enforcement. The separate withdrawn-nomination table records withdrawal, with safety concerns still published.
Three ingredients, three unresolved obligations
For BPC-157, FDA describes immunogenicity and peptide-impurity concerns—the possibility of an immune reaction and difficulties characterizing unwanted material. For TB-500, the same record cites immune risks and missing safety information. Injectable GHK-Cu also remains in that withdrawn-nomination record. The blend does not erase any ingredient's requirements.
Topical Copper Tripeptide-1 is a separate cosmetic use. The cosmetic-versus-drug distinction does not make a cosmetic an FDA-approved drug and does not authorize a GHK-Cu injection. For pharmacy law, that change of route is decisive.
The published July 23-24, 2026 advisory agenda names BPC-157 and TB-500 as candidates for consideration for the 503A bulk list; GHK-Cu is not named there. That document is an agenda, not documentation of a final FDA listing decision. It cannot establish current ingredient eligibility or permission to compound a GLOW injection.
Each pharmacy still has ingredient rules to satisfy
A state-licensed 503A pharmacy fills a valid patient-specific prescription within the applicable conditions. A 503B outsourcing facility registers with FDA and may prepare larger batches under stricter requirements. The FDA compounding framework still limits the bulk substances that can be used.
A clinician may prescribe after reviewing a request, or may decline. A prescription does not itself make a restricted ingredient eligible for pharmacy preparation, and a video visit does not change the ingredient rules. State and treatment limits also matter. The compounded GLOW blend has no FDA approval.
To me, “available” is too loose a word to carry all of that. It can obscure the clinical assessment, the ingredient's legal basis and the pharmacy's separate obligations. Neither a withdrawn nomination nor an advisory agenda settles those obligations for a particular preparation. This page gives general information about the published record, not legal advice for a person's case.